Knee Osteoarthrosis (KOA) in Jordanian Patients: a Phase I Dose-finding Study Using Extracellular Vesicles (EV) for Advanced Stage III and IV KOA
Sponsor study identifier
interventional
50
1 country
1
Study Start
January 1, 2024
Actual (reported)Primary Completion
January 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Extracellular vesicles (EV) will be injected in patients diagnosed with Knee osteoarthrosis
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
January 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 1, 2024
Actual (reported)February 27, 2024
Actual (reported)April 22, 2025
Actual (reported)January 30, 2026
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
January 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Safety
Measuring and evaluating the Safety and Tolerability of the intra-articular injection of extracellular vesicles: Complete Blood Count (CBC): Hemoglobin (Hb) Hematocrit (Hct) White blood cells (WBCs) Platelets (PLTs) Red blood cell indices (MCV, MCH, MCHC) A. Liver Function Tests (LFTs) Alanine aminotransferase (ALT) Asparate aminotransferase (AST) Alkaline phosphatase (ALP) Gamma-glutamyl transferase (GGT) Total bilirubin (TBIL), Direct \& Indirect bilirubin Albumin and total protein B. Kidney Function Tests Blood Urea Nitrogen (BUN) Serum Creatinine Uric Acid Estimated Glomerular Filtration Rate (eGFR) C. Electrolyte Panel Sodium (Na⁺) Potassium (K⁺) Calcium (Ca²⁺) Magnesium (Mg²⁺) Chloride (Cl-) Bicarbonate (HCO₃-) D. Glucose \& Lipid Profile Fasting blood glucose (FBG) Total cholesterol, HDL, LDL, Triglycerides Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) INR (International Normalized Ratio)
follow-up duration is 12 months
Efficacy
follow-up duration is 12 months
Intra-articular Extracellular vesicles injection will be given to each patient in 2 doses
Intra-articular extravascular vesicles injection.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Cell Therapy Center
Amman, 00962, Jordan
First Submitted
February 27, 2024
First Posted
April 22, 2025
Study Start
January 1, 2024
Actual (reported)Primary Completion
January 30, 2026
Estimated (date passed)Treatment of Knee Arthrosis With Platelet-derived Growth Factors vs. Hyaluronic Acid.
Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
January 30, 2027
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
April 22, 2025
Record last verified: 2025-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: